Business
INOVIO Reports Third Quarter 2021 Financial Results
INOVIO receives U.S. FDA authorization to proceed with INNOVATE Phase 3 segment for its COVID-19 vaccine candidate, INO-4800, in the U.S. INOVIO has
About this update from Inovio Pharmaceuticals, Inc.
[{"type":"text","content":"INOVIO receives U.S. FDA authorization to proceed with INNOVATE Phase 3 segment for its COVID-19 vaccine candidate, INO-4800, in the U.S.\n INOVIO has regulatory authorization for global Phase 3 trial for INO-4800 in seven countries, including most recently announced Thailand; Dosing for INNOVATE Phase 3 underway\n INO-4800 is one of two vaccine candidates initially selected for WHO's Phase 3 Solidarity Trial Vaccines\n Investor Call Today at 4:30 PM ET\n\n\nPLYMOUTH MEETING, Pa., Nov. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat people with cancer, and HPV-associated diseases, today reported financial results for the quarter ended September 30, 2021. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss financial results and provide a general business update. The live webcast and replay may be accessed by visiting INOVIO's website at http://ir.inovio.com/events-and-presentations/default.aspx. \nDr. J. Joseph Kim, President and CEO of INOVIO, said, \"This morning, INOVIO announced that the U.S. Food and Drug Administration (FDA) provided authorization to proceed for INOVIO's INNOVATE Phase 3 segment for its COVID-19 vaccine candidate, INO-4800, in the U.S. We're pleased to have the opportunity for U.S. clinical trial participants to potentially contribute to the enrollment in our INNOVATE Phase 3 segment. Today's U.S. announcement builds on our intensive global efforts in India, Brazil, Philippines, Mexico, Colombia, and Thailand where we have received authorizations to date. \n\"With much of the world still requiring broader access to vaccines, INO-4800 is particularly well-positioned to address global vaccine needs, having been shown, in clinical trials to-date, to be well-tolerated and to generate balanced immune responses which comprise both T and B cell engagement. In addition, INO-4800 has demonstrated a favorable thermostability profile that could facilitate global distribution. I am pleased to share that the dosing for INNOVATE Phase 3 segment is underway and we aim to have interim efficacy data in the first half 2022.\"\nINOVIO Key Updates & Third Quarter 2021 Highlights \nKey Updates\nINOVIO announced that the U.S. ...